All In Biotech

NDA 215974 · Gilead Sciences INC

Sunlenca

Lenacapavir Sodium · Oral

NovelBreakthrough therapyPriority review

Last checked: Nov 19, 2026Latest source record: Aug 27, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Dec 22, 2022

Approved uses

3

Original approval plus efficacy supplements

Registered trials

34

15 Phase 3, 12 recruiting

FAERS reports

2

1 serious, 0 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

SUNLENCA, a human immunodeficiency virus type 1 (HIV-1) capsid inhibitor, is indicated: in combination with other antiretroviral(s), for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. ( 1.1 ) for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for the treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO. ( 1.2 ) 1.1 Treatment of HIV-1 in Heavily Treatment-Experienced Adults SUNLENCA, in combination with other antiretroviral(s), is indicated for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in heavily treatment-experienced adults with multidrug resistant HIV-1 whose current antiretroviral regimen is failing due to resistance, intolerance, or safety considerations. 1.2 Oral Loading for Initiation of BIXLENVO SUNLENCA tablets are indicated for oral loading as a component of the initiation regimen for BIXLENVO (bictegravir [BIC]/lenacapavir [LEN]), a complete regimen for treatment of HIV-1 infection, in adults to replace the current antiretroviral regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen with no known or suspected resistance to the individual components of BIXLENVO [see Dosage and Administration (2.3) ] .

Mechanism: SUNLENCA is an HIV-1 antiretroviral agent [see Microbiology (12.4) ] .

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Aug 27, 2026 Supplement 17 · Efficacy LetterLabel
  • Nov 25, 2024 Supplement 8 · Efficacy LabelLetter
  • Dec 22, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelBreakthrough therapyLabelLetterReview
1 products under this application
  • SUNLENCA · LENACAPAVIR SODIUM EQ 300MG BASE · TABLET, ORAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Lenacapavir" as an intervention, any sponsor and status, largest first.

All 34 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dizziness1
  • human immunodeficiency virus transmission1
  • hyperhidrosis1
  • maternal exposure during pregnancy1
  • nausea1

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20251
20261

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Sunlenca* (Lenacapavir Sodium)

2024 spending

$18.3M

Beneficiaries

596

1,253 claims

Per beneficiary

$30,728

$4,799.66 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$9,723,618
2024$18,314,069

Part B: Sunlenca (Lenacapavir Sodium) · HCPCS J1961

2024 spending

$753K

Beneficiaries

36

50 claims

Per beneficiary

$20,922

2024 ASP limit $21.96 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$753,200

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 44 on PubMed

Sponsor: Gilead Sciences

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.